-- BioMarin Pharmaceutical (BMRN) 周一宣布，已完成此前公布的对 Amicus Therapeutics (FOLD) 的收购，收购金额为 48 亿美元。 该公司表示，此次交易将 Galafold（一种用于治疗法布里病的口服药物）和 Pombiliti（一种与 Opfolda 联合用于治疗庞贝病的药物）纳入 BioMarin 的产品组合。 BioMarin 还表示，该公司已获得在美国治疗局灶节段性肾小球硬化症的在研疗法 DMX-200 的权益。 该公司股价在周一的交易中上涨超过 1%。
Price: $53.60, Change: $+0.42, Percent Change: +0.79%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PSA reported Q1 revenue of $1.21B, up 2.9% from $1.18B in Q1 2025 and $7M ahead of consensus estimates. Same-store performance showed continued stabilization with revenue now flat at $1.0B, while NOI increased 0.4% to $739M, marking a positive inflection point. Declining repairs and maintenance costs (-5.8%) and marketing expenses (-4.5%) created meaningful tailwinds for positive same-store NOI growth in Q1, demonstrating effective cost management. Despite the improvement in same-store revenue and NOI performance in Q1, PSA maintained its prior guidance for same-store NOI growth down 3.9% to down 0.5% for FY 26. The company's disciplined cost management initiatives appear to be supporting margin expansion even as revenue growth remains modest across the portfolio. We believe the maintained guidance suggests management remains appropriately cautious about the broader operating environment despite the encouraging Q1 stabilization trends in key metrics.
Celestica (CLS.TO, CLS) shares were last seen down 8.6% in after-hours New York trading after the company on Monday reported higher first-quarter profit and revenue and raised 2026 outlook.The data-center infrastructure company said its adjusted earnings, excluding most one-time items, rose to US$249.5 million, or US$2.16 per share, up from US$140.1 million, or US$1.20, in the year-prior quarter. FactSet expected US$2.07 per share.Revenue rose to US$4.05 billion from US$2.65 billion in the year-ago quarter. FactSet estimated US$4.04 billion."We continue to see accelerating growth from our CCS customer base, alongside increasing profitability in both our CCS and ATS segments. Driven by this momentum, we are raising our 2026 annual outlook to US$19 billion in revenue and US$10.15 in adjusted EPS (non-GAAP). Our outlook for 2027 also continues to strengthen from just 90 days ago, supported by new program wins as well as improved forecast visibility with our customers," Chief Executive Rob Mionis said.For the second quarter, the company expects revenue to range between US$4.15 billion and US$4.45 billion, and adjusted earnings per share are expected to be between US$2.14 and US$2.34.Celestica shares were last seen down US$36.21 to US$386.00. They closed up C$15.74 to C$576.75 on the Toronto Stock Exchange.
Ranger Energy Services (RNGR) reported Q1 earnings Monday of $0.12 per diluted share, up from $0.03 a year earlier.One analyst polled by FactSet expected $0.13.Revenue in the three months ended March 31 rose to $159.1 million from $135.2 million a year earlier.Three analysts surveyed by FactSet expected $156.2 million.Ranger Energy shares fell 10% in after-hours trading.